Skip to content

ESA ASM 2018

Wednesday, 31 October 2018 to Friday, 2 November 2018 from 11:30 AM - 2:00 PM

Brisbane Convention and Exhibition Centre, Brisbane, Australia


Scientific Program

The preliminary scientific program is available for download on the right hand side of this page.

JF good.jpg

Organisation: NYU Langone School of Medicine

Position: Professor of Neurology

Dr. Jacqueline French is a professor of Neurology in the Comprehensive Epilepsy Center at NYU Langone School of Medicine and Founder/Director of the Epilepsy Study Consortium, an academic group that has performed a number of early phase clinical trails in epilepsy, and has developed new methodologies for epilepsy trials. Dr. French trained in Neurology at Mount Sinai Hospital in New York, and did her fellowship training in EEG and epilepsy at Mount Sinai hospital and Yale University.

Dr French has focused her research efforts on development of new therapeutics for epilepsy, and new methodologies for clinical trials. Over the past 20 years she has served as the Principle investigator on a number of trials for new epilepsy drugs. She is responsible for creation of a number of new trial designs that have been accepted by regulatory authorities for new drug approval. Dr. French has been active in creating guidelines for the American Academy of Neurology and the International League Against Epilepsy. She chaired an AAN/AES committee that produced two widely quoted guidelines on the use of new antiepileptic drugs. She has served as chair of the International League Against Epilepsy North American Regional Commission, and Commission on Therapeutic strategies. Dr. French serves as the Chief Scientific Officer of the Epilepsy Foundation. She is the past president of the American Epilepsy Society. She is the past Secretary of the American Society of Experimental Neurotherapeutics. She andand is the recipient of the American Epilepsy Society Lennox Award (2017) and Service Award (2005), the Epilepsy Foundation Hero award (2013), and is an ILAE Embassador for Epilepsy. She has authored over 200 articles and chapters, is the editor of three books, and lectures internationally on clinical trials and use of antiepileptic drugs.

sean-pittock-12928674 (2).jpeg

Organisation: Mayo Clinic

Position: Director of Mayo Clinic's Center for Multiple Sclerosis and Autoimmune Neurology and of Mayo's Neuroimmunology Research

Sean Pittock, MB, MMed Sci, M.D., is a consultant in the Department of Neurology and has a joint appointment in the Department of Laboratory Medicine and Pathology. He holds the academic rank of professor of neurology, Mayo Clinic College of Medicine. He currently serves as director of the Neuroimmunology Laboratory and is the Marilyn A. Park and Moon S. Park, M.D., Director of the Center for Multiple Sclerosis and Autoimmune Neurology. In 2006, he set up the Autoimmune Neurology Clinic at the Mayo Clinic, the first dedicated Clinic of its type in the USA. This Clinic provides a multidisciplinary approach to the evaluation and treatment of patients with a broad range of autoimmune neurological disorders considered "rare orphan diseases". These disorders have often been misdiagnosed as untreatable neurodegenerative diseases; but are, in fact, responsive to immunotherapy and reversible. Dr Pittock's research is translational, and is focused on 1) the identification of novel biomarkers of autoimmune neurological diseases, 2) the clinical application of laboratory-based tests in diagnosis and outcome prediction for patients with autoimmune neurological disorders and 3) optimizing the clinical management of autoimmune neurological disorders. His recent work has focused on the diagnostic characteristics and immunotherapy outcomes of patients with autoimmune CNS demyelinating disorders (targets include aquaporin-4), dementias (target includes voltage-gated potassium channels), epilepsies (targets include NMDA receptors) and gastrointestinal dysmotility (targets include ganglionic acetylcholine receptors). This unique translational practice extending the laboratory's serologic findings directly to the bedside has allowed the creation of diagnostic decision trees which will optimize triaging of such patients for further phenotype analysis and biomarker discovery. He is currently Vice Chair of the section for Autoimmune Neurology at the AAN. He is actively involved in educational courses at both national (American Academy of Neurology, American Neurological Association) and international (World Congress of Neurology) meetings.